Bridged amino tetralins.
D000700:Analgesics / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D000818:Animals; D001952:Bridged-Ring Compounds / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D003496:Cyclazocine / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004597:Electroshock; D000882:Haplorhini; D006801:Humans; D008251:Macaca; D051379:Mice; D009020:Morphine / Q000037:antagonists & inhibitors; D009021:Morphine Dependence; D009269:Nalorphine / Q000494:pharmacology; D009270:Naloxone / Q000494:pharmacology; D009281:Naphthalenes / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D009292:Narcotic Antagonists / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D010423:Pentazocine / Q000494:pharmacology; D004856:Postural Balance / Q000187:drug effects; D051381:Rats; D011930:Reaction Time / Q000187:drug effects; D012018:Reflex / Q000187:drug effects; D013375:Substance Withdrawal Syndrome / Q000139:chemically induced; D013623:Tail
D000700:Analgesics; D001952:Bridged-Ring Compounds; D009281:Naphthalenes; D009292:Narcotic Antagonists; D009270:Naloxone; D009020:Morphine; D003496:Cyclazocine; D010423:Pentazocine; D009269:Nalorphine